Through cell engineering, Gameto is developing an ecosystem
of therapeutics to support modern women throughout
their reproductive journeys.
Women are born with a finite number of eggs–all of the eggs they will ever have. As women age, the number and quality of these eggs decline throughout their lifetime, causing a number of problems with the female reproductive system. Notably, the relative decline leads to infertility, and the absolute decline causes menopause.
This decline is not a biological imperative. Only humans and four types of whales even experience menopause. With few species experiencing this decline in ovarian health, studying the female reproductive system is challenging.
Gameto has developed a platform to produce female reproductive cell lines. We use proprietary cell engineering to generate ovarian cell lines that mimic the functions of reproductive system cells, producing and responding to all hormones.
Our team of engineers is using this platform to build a portfolio of cellular therapeutics for women’s health.
Gameto is currently developing the first application of this platform, Fertilo, which is a technology designed to improve assisted fertility outcomes.
We are currently focused on improving fertility care outcomes, but what we are currently doing for infertility, we will soon do for drug development, menopause, and much more...
We are working on applications that address women’s reproductive health, including assisted fertility outcomes, ovarian disease, menopause, and more.